The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 407-414

  Jarell, Abel D ^a   Lawrence, Donald ^b   Tsao, Hensin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Malignant melanoma; MAP kinase; RAS; Therapeutics

Indexed keywords

EID: 79960102651     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Phase III Trial of Nexavar in patients with advanced melanoma does not meet primary endpoint. Press Release published by Onyx Pharma-ceuticals, Inc. Accessed 12/4/2006. http://www.onyx-pharm.com/wt/ page/pr_1165242111.
2. Amaravadi RK, Schuchter LM, Kramer A, et al. 2006. 2006 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology, 24(18S):8009.
3. Amiri P, Aikawa M, Dove J, et al. 2006. CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. 97th AACR annual meeting. Washington, DC.
4. Beeram M, Patnaik A, Rowinsky EK. 2005. Raf: a strategic target for thera-peutic development against cancer. J Clin Oncol, 23:6771-90.
5. Bennett DC. 2003. Human melanocyte senescence and melanoma suscep-tibility genes. Oncogene, 22:3063-9.
6. Boulton TG, Cobb MH. 1991. Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul, 2:357-71.
7. Boulton TG, Nye SH, Robbins DJ, et al. 1991. ERKs: a family of proteinserine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell, 65:663-75.
8. Brose MS, Volpe P, Feldman M, et al. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res, 62:6997-7000.
9. Carlomagno F, Anaganti S, Guida T, et al. 2006. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst, 98:326-34.
10. Chung NM, Gutierrez M, Turner ML. 2006. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol, 142:1510-11.
11. Cohen C, Zavala-Pompa A, Sequeira JH, et al. 2002. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res, 8:3728-33.
12. Curtin JA, Busam K, Pinkel D, et al. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol, 24:4340-6.
13. Davies H, Bignell GR, Cox C, et al. 2002. Mutations of the BRAF gene in human cancer. Nature, 417:949-54.
14. Der CJ, Krontiris TG, Cooper GM. 1982. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA, 79:3637-40.
15. Dicker AP, Volkenandt M, Albino AP. 1990. Mutational analysis of human NRAS genes in malignant melanoma: rapid methods for oligonucleotide hybridization and manual and automated direct sequencing of products generated by the polymerase chain reaction. Genes Chromosomes Cancer, 1:257-69.
16. Druker BJ. 2002. Perspectives on the development of a molecularly targeted agent. Cancer Cell, 1:31-6.
17. Eisen T, Ahmad T, Flaherty KT, et al. 2006. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer, 95:581-6.
18. Escudier B, Eisen T, Stadler WM, et al. 2007. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med, 356:125-34.
19. Flaherty KT. 2006. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin Cancer Res, 12:2366s-2370s.
20. Flaherty KT, Brose M, Schuchter L, et al. 2004. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Journal of Clinical Oncology, 22(14S):7507.
21. Fletcher JA, Rubin BP. 2007. KIT mutations in GIST. Curr Opin Genet Dev, 17:3-7.
22. Garraway LA, Weir BA, Zhao X, et al. 2005. "Lineage addiction" in human cancer: lessons from integrated genomics. Cold Spring Harb Symp Quant Biol, 70:25-34.
23. Garraway LA, Widlund HR, Rubin MA, et al. 2005. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436:117-22.
24. Gotlib J. 2006. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am, 26:575-92.
25. Gray-Schopfer V, Wellbrock C, Marais R. 2007. Melanoma biology and new targeted therapy. Nature, 445:851-7.
26. Gray-Schopfer VC, Karasarides M, Hayward R, et al. 2007. Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res, 67:122-9.
27. Hahn O, Stadler W. 2006. Sorafenib. Curr Opin Oncol, 18:615-21.
28. Hall-Jackson CA, Eyers PA, Cohen P, et al. 1999. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol, 6:559-68.
29. Haluska FG, Tsao H, Wu H, et al. 2006. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res, 12:2301s-2307s.
30. Heimbrook D, Huber H, Stirdivant S, et al. 1998. Identification of potent, selective kinase inhibitors of Raf. American Association of Cancer Research, p. 558.
31. Hingorani SR, Jacobetz MA, Robertson GP, et al. 2003. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res, 63:5198-202.
32. Hocker T, Tsao H. 2007. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat.
33. Hussein MR. 2006. Expression of KIT receptor tyrosine kinase protein in normal human skin: Preliminary observations. Cell Biol Int.
34. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
35. Johnston SR. 2001. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol, 2:18-26.
36. Karasarides M, Chiloeches A, Hayward R, et al. 2004. B-RAF is a therapeutic target in melanoma. Oncogene, 23:6292-8.
37. Khire UR, Bankston D, Barbosa J, et al. 2004. Omega-carboxypyridyl sub-stituted ureas as Raf kinase inhibitors: SAR of the amide substituent. Bioorg Med Chem Lett, 14:783-6.
38. Lackey K, Cory M, Davis R, et al. 2000. The discovery of potent cRaf1 kinase inhibitors. Bioorg Med Chem Lett, 10:223-6.
39. Lorusso PM, Adjei AA, Varterasian M, et al. 2005. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol, 23:5281-93.
40. Macgregor JL, Silvers DN, Grossman ME, et al. 2007. Sorafenib-induced erythema multiforme. J Am Acad Dermatol.
41. Mayo MW, Wang CY, Cogswell PC, et al. 1997. Requirement of NF-kappaB activation to suppress p 53-independent apoptosis induced by oncogenic Ras. Science, 278:1812-15.
42. Mesa RA. 2006. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther, 6:313-19.
43. Morgillo F, Lee HY. 2006. Lonafarnib in cancer therapy. Expert Opin Investig Drugs, 15:709-19.
44. Niculescu-Duvaz I, Roman E, Whittaker SR, et al. 2006. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem, 49:407-16.
45. Ouyang B, Knauf JA, Smith EP, et al. 2006. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, 12:1785-93.
46. Panka DJ, Wang W, Atkins MB, et al. 2006. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res, 66:1611-19.
47. Pickle LW, Hao Y, Jemal A, et al. 2007. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin, 57:30-42.
48. Ratain MJ, Eisen T, Stadler WM, et al. 2006. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24:2505-12.
49. Rodriguez-Viciana P, Tetsu O, Oda K, et al. 2005. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol, 70:461-7.
50. Roussidis AE, Theocharis AD, Tzanakakis GN, et al. 2007. The Importance of c-Kit and PDGF Receptors as Potential Targets for Molecular Therapy in Breast Cancer. Curr Med Chem, 14:735-43.
51. Satyamoorthy K, Li G, Gerrero MR, et al. 2003. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res, 63:756-9.
52. Schnadig ID, Blanke CD. 2006. Gastrointestinal stromal tumors: imatinib and beyond. Curr Treat Options Oncol, 7:427-37.
53. Schreck R, Rapp UR. 2006. Raf kinases: oncogenesis and drug discovery. Int J Cancer, 119:2261-71.
54. Smalley KS, Eisen TG. 2003. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer, 105:165-75.
55. Solit DB, Garraway LA, Pratilas CA, et al. 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439:358-62.
56. Sosman JA, Puzanov I. 2006. Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res, 12:2376s-2383s.
57. Steingrimsson E, Copeland NG, Jenkins NA. 2004. Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet, 38:365-411.
58. Strumberg D. 2005. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc), 41:773-84.
59. Stuart D, Aardalen K, Lorenzana E, et al. 2006. Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf. 97th AACR annual meeting. Washington, DC.
60. Takle AK, Brown MJ, Davies S, et al. 2006. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett, 16:378-81.
61. Tomita Y. 1994. The molecular genetics of albinism and piebaldism. Arch Dermatol, 130:355-8.
62. Tsai J, Zhang J, Bremer R, et al. 2006. Development of a novel inhibitor of oncogenic B-RAF. 97th AACR annual meeting. Washington, DC.
63. Tsao H, Atkins MB, Sober AJ. 2004. Management of cutaneous melanoma. N Engl J Med, 351:998-1012.
64. Tsao H, Goel V, Wu H, et al. 2004. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol, 122:337-41.
65. Ugurel S, Hildenbrand R, Zimpfer A, et al. 2005. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer, 92:1398-405.
66. Uribe P, Wistuba, II, Gonzalez S. 2003. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol, 25:365-70.
67. Venetsanakos E, Stuart D, Tan N, et al. 2006. CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models. 97th AACR annual meeting.Washington,DC.
68. Veronese ML, Mosenkis A, Flaherty KT, et al. 2006. Mechanisms of hyper-tension associated with BAY 43-9006. J Clin Oncol, 24:1363-9.
69. Wan PT, Garnett MJ, Roe SM, et al. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 116:855-67.
70. Whitwam T, Vanbrocklin MW, Russo ME, et al. 2007. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene.
71. Wilhelm S, Chien DS. 2002. BAY 43-9006: preclinical data. Curr Pharm Des, 8:2255-7.
72. Wilhelm SM, Carter C, Tang L, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64:7099-109.
73. Wyman K, Atkins MB, Prieto V, et al. 2006. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer, 106:2005-11.